Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regulus Therapeutics Inc. - Common Stock (NQ: RGLS )

1.210 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regulus Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Why ViewRay Shares Are Trading Lower By 32%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers CXApp Inc. (NASDAQ: CXAI) jumped 105% to $3.28 after climbing over 20% on Wednesday. 
Via Benzinga
Why Regulus Therapeutics Shares Are Trading Higher Today
Regulus Therapeutics (NASDAQ: RGLS) shares are trading higher on Thursday after the company announced a $15 million private placement of equity. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Earnings Outlook For Regulus Therapeutics
Via Benzinga
Earnings Scheduled For August 11, 2022
Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million. 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Sanofi Opts To Terminate Rare Disease Program With Regulus Therapeutics
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares rose 49.1% to $3.22 during Tuesday's pre-market session. The company's market cap stands at $2.8 million. 
Via Benzinga
Earnings Scheduled For November 10, 2022
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report earnings for its third quarter. 
Via Benzinga
Targeting Autosomal Dominant Polycystic Kidney Disease With Novel Approaches
Approximately 160,000 individuals in the United States are diagnosed with polycystic kidney disease, and the global prevalence of the condition is estimated at between 4 million and 7 million people. 
Via Benzinga
Why Tuesday Morning Shares Tumbled 31%; Here Are 66 Biggest Movers From Yesterday
Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 101.3% to settle at $0.5558 on Monday after the company announced a 1-for-30 reverse stock split. 
Via Benzinga
Important Biotech Catalysts For September 12, 2022 - End Of The Day Summary
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
  
Via Benzinga
Why Ventyx Biosciences Is Trading Higher By 70%, Here Are 46 Stocks Moving In Monday's Mid-Day Session
Gainers Ventyx Biosciences, Inc. (NASDAQ: VTYX) shares jumped 70.4% to $39.37 after Oppenheimer maintained an Outperform rating on the stock and raised its price target from $40 to $65. 
Via Benzinga
Regulus Shares Surge After Early-Stage RGLS8429 Data In Rare Kidney Disease
Biopharmaceutical company Regulus Therapeutics Inc (NASDAQ: RGLS) shares jumped after topline safety and Pharmacokinetic (PK) data from its Phase 1 single-ascending dose (SAD) trial of RGLS8429 in... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
  
Via Benzinga
Why Allena Pharmaceuticals Tumbled Over 30%; Here Are 85 Biggest Movers From Yesterday
Gainers Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) shares jumped 91.3% to close at $28.50 on Tuesday amid post-IPO volatility. 
Via Benzinga
Why HyreCar Is Trading Higher By 60%, Here Are 63 Stocks Moving In Tuesday's Mid-Day Session
Gainers HyreCar Inc. (NASDAQ: HYRE) jumped 60% to $1.2680 after the company announced it has received a $100 million revolving line of credit from a premier global investment bank and Medalist... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
  
Via Benzinga
Amid RNA Setbacks, Start Up Bets On Sanofi's siRNA Platform
Via Benzinga
The Daily Biotech Pulse: Sesen Bio Stops Lead Assest Development In US, FDA Approves Eton Pharma's Partial Seizures Drug, Bavarian Nordic Inks Multiple Supply Pact For Monkeypox Vaccine
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
  
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Recap of Tuesday's Biotech Catalysts - End of the Day Summary
Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid... 
Via Benzinga
Regulus Gets FDA Orphan Drug Status For Kidney Disease Candidate
Regulus Therapeutics Inc. (NASDAQ: RGLS) received orphan drug designation from the U.S. Food and Drug Administration (FDA) for its lead drug RGLS8429 in the treatment of Autosomal Dominant Polycystic... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.